Insulin Therapy Recommendations for Type 1 Diabetes

Treatment Modality

• Most individuals with type 1 diabetes should be managed with multiple‑dose insulin (MDI) injections (three to four daily doses of basal and prandial insulin) or continuous subcutaneous insulin infusion (CSII) using insulin analogs to lower hypoglycemia risk. 1

Initial Insulin Dosing

• The total daily insulin dose (TDD) for metabolically stable patients is generally 0.4–1.0 units kg⁻¹ day⁻¹, with 0.5 units kg⁻¹ day⁻¹ often used as a starting point. 2
• The TDD is typically split ≈ 50 % basal insulin and 50 % prandial insulin to provide continuous background coverage and to address post‑prandial glucose excursions across three meals. 1

Basal Insulin Selection & Administration

• Long‑acting insulin analogs (glargine, detemir, degludec) are preferred over NPH insulin because they deliver a flatter, more constant plasma profile and reduce hypoglycemia. 1
• Basal analogs are administered once daily at the same time each day to maintain steady coverage. 2

Prandial Insulin Selection & Timing

• Rapid‑acting insulin analogs (aspart, lispro, glulisine) are recommended instead of regular human insulin due to faster onset, higher peak, and shorter duration, which better matches meal glucose spikes. 1
• These analogs should be injected 0–15 minutes before meals for optimal post‑prandial control. 2
• Faster‑acting insulin aspart provides superior post‑prandial glucose coverage compared with standard rapid‑acting analogs. 2

Patient Education

• Patients must be taught to match prandial insulin to carbohydrate intake, pre‑meal blood glucose, and anticipated activity to achieve individualized dosing. 1
• More frequent self‑monitoring of blood glucose is advised during illness, exercise, or when dose adjustments are being made. 2

Basal Insulin Titration & Glycemic Targets

• Basal insulin should be re‑evaluated every 3 days based on fasting glucose patterns. 2
• The target fasting glucose range is 80–130 mg/dL. 2

Special Populations Requiring Dose Adjustments

• Puberty: Insulin requirements often rise, frequently approaching ≈ 1.0 units kg⁻¹ day⁻¹ or higher. 2
• Pregnancy: Higher insulin doses are needed throughout gestation to maintain glycemic control. 2

Injection Technique

• Preferred injection sites include the abdomen, thigh, buttock, and upper arm. 2
• Injection sites should be rotated to prevent lipohypertrophy. 2
• All injections must be subcutaneous, avoiding intramuscular delivery, especially with long‑acting insulins, to reduce the risk of severe hypoglycemia. 2

Insulin Dosing Guidelines for Type 1 Diabetes

Initial Dosing Calculation

• The American Diabetes Association recommends starting with 0.5 units/kg/day as the baseline total daily insulin dose (TDD) for metabolically stable patients with type 1 diabetes, with an acceptable range of 0.4-1.0 units/kg/day 3, 4, 5, 6, 7, 8, 9, 10, 11
• For patients presenting with diabetic ketoacidosis, higher weight-based dosing than the standard 0.5 units/kg/day is recommended 3, 5
• For young children and those in the "honeymoon period" with residual endogenous insulin production, lower doses of 0.2-0.6 units/kg/day are suggested 4

Distribution Between Basal and Prandial Insulin

• The American Diabetes Association's 2024 guidelines recommend 30-50% of TDD as basal insulin, with the remainder as prandial insulin 4
• The 2019-2021 guidelines suggest 50% basal and 50% prandial insulin 10, 11
• The 2017-2018 guidelines recommend approximately 50% basal and 50% prandial insulin 3, 5, 6, 7

Special Populations Requiring Dose Adjustments

• Higher insulin doses (approaching 1.0 units/kg/day or more) are required during puberty 3, 4, 8, 9
• Higher insulin doses are also required during pregnancy 8, 10, 11
• Medical illness, such as infections or inflammation, may require higher insulin doses 4, 8, 9, 10, 11
• Menses may also require higher insulin doses 4

Evidence‑Based Recommendations for Type 1 Diabetes Management

Insulin Analogs vs. Human Insulin

• Long‑acting basal analogues (glargine, detemir, degludec) provide a flatter, more constant plasma insulin profile than NPH insulin and significantly lower the risk of overall and nocturnal hypoglycemia. 12
• Rapid‑acting prandial analogues (aspart, lispro, glulisine) have a faster onset, higher peak, and shorter duration than regular human insulin, resulting in better matching of post‑prandial glucose excursions and a reduced hypoglycemia risk. 12
• The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive therapy with older human insulins cut microvascular complications by ≈ 50 % but produced 62 severe hypoglycemia episodes per 100 patient‑years; use of insulin analogues mitigates this hypoglycemia burden. 12

Initial Dosing Guidance

• The 2024 American Diabetes Association (ADA) guidelines permit basal insulin to comprise 30 %– 50 % of the total daily dose (TDD); a 50 % basal / 50 % prandial split is the most frequently recommended starting point. 12

Advanced Insulin Delivery

• Automated insulin delivery (AID) systems should be considered for all adults with type 1 diabetes because they improve time‑in‑range, lower HbA1c, and reduce hypoglycemia incidence. 12
• Hybrid closed‑loop AID systems are superior to sensor‑augmented pump therapy alone for increasing time‑in‑range and decreasing hypoglycemia. 12
• Continuous subcutaneous insulin infusion (CSII) via pump therapy offers modest advantages over multiple‑daily‑injection (MDI) regimens in lowering HbA1c and reducing severe hypoglycemia in both children and adults. 12

Treatment Reassessment

• Insulin treatment plans should be re‑evaluated every 3 – 6 months, with adjustments based on insulin‑taking behavior, cost considerations, and other factors influencing therapy choice. 12

Evidence‑Based Recommendations for Type 1 Diabetes Management

Insulin Therapy Regimen

• Most individuals with type 1 diabetes should receive multiple‑daily‑injection (MDI) therapy or continuous subcutaneous insulin infusion (CSII) using insulin analogs rather than human insulins to lower the risk of hypoglycemia. 13
• During puberty, total daily insulin requirements often increase to approximately 1 unit/kg/day or higher. 13
• Rapid‑acting insulin analogs (aspart, lispro, or glulisine) are recommended to be administered 0–15 minutes before meals to improve post‑prandial glucose control. 13

Patient Education & Insulin Dose Adjustment

• Patients should be taught to adjust prandial insulin doses based on carbohydrate amount, pre‑meal glucose level, and anticipated physical activity. [13][14]
• After mastering carbohydrate counting, education should be extended to estimating fat and protein grams to fine‑tune insulin dosing. 13

Insulin Pump (CSII) Access

• Adults who are successfully using CSII should retain access to pump therapy beyond age 65. 13

Glycemic Monitoring for Sub‑optimal HbA1c

• When fasting glucose values are within target but HbA1c remains above goal, patients should check post‑prandial plasma glucose 1–2 hours after meals and aim for values < 180 mg/dL. 14

Cardiovascular Risk Factor Management

• Low‑density lipoprotein (LDL) cholesterol should be kept < 100 mg/dL (2.6 mmol/L); for high‑risk individuals, a target < 70 mg/dL is advisable. 15
• Blood pressure goals are < 130/80 mm Hg. 15
• A daily low‑dose aspirin regimen reduces coronary heart disease risk by approximately 20–25 %. 15
• Smoking cessation is recommended to lower the risk of cardiovascular disease and microvascular complications. 15

Screening for Diabetes‑Related Complications

• Dilated retinal examinations should be performed annually beginning 3–5 years after diabetes onset. 15
• Annual screening for microalbuminuria is advised to detect early nephropathy. 15

Dietary Recommendations

• Total fat intake should not exceed 30 % of total calories, with saturated fat limited to < 7 % of calories. [15][14]
• Sodium consumption should be limited to ≤ 1,500 mg per day. 15
• Patients should aim for at least 14 g of dietary fiber per 1,000 kcal and include whole‑grain foods. 14
• Daily intake should include roughly 3 oz of whole grains, 2 cups of fruit, and 3 cups of vegetables. 15
• Carbohydrate intake should be monitored using counting methods, exchange lists, or experience‑based estimation. 14

Hypoglycemia Prevention & Management

• Patients must be educated on the signs and symptoms of hypoglycemia and appropriate treatment steps. 15
• A rapid source of carbohydrate (e.g., glucose tablets) should be carried at all times. 15
• Glucagon should be kept readily available for severe hypoglycemia. 15
• Family members and close contacts should receive training on hypoglycemia recognition and assistance. 15

Lifestyle Modifications

• Regular physical activity is encouraged. 15
• Maintaining a healthy body weight is recommended. 15
• Alcohol consumption should be limited to moderate amounts. 15
• Stress management strategies should be employed to mitigate glucose fluctuations. 15
• Wearing a medical alert bracelet or necklace is advised for emergency identification. 15